

*The information in the press release is intended for investors.*

## Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

**GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 8, 2024.**

The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the annual general meeting held on Wednesday, May 8, 2024 at 2 p.m. at Biotech Center, Arvid Wallgrens backe 20, Fl. 5, Gothenburg, Sweden. Registration at the annual general meeting starts at 1:30 p.m. and ends when the meeting convenes.

The complete notice to attend is available in Swedish on the company's website, [www.isofolmedical.com](http://www.isofolmedical.com)

### **For further information, please contact**

**Isofol Medical AB (publ)**  
Magnus Hurst, CFO  
E-mail: [magnus.hurst@isofolmedical.com](mailto:magnus.hurst@isofolmedical.com)  
Telephone: +46 (0)738 73 34 18

*The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on April 5, 2024.*

### **About Isofol Medical AB (publ)**

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

[www.isofolmedical.com](http://www.isofolmedical.com)